An analytic dosimetry study for the use of radionuclide-liposome conjugates in internal radiotherapy

dc.contributor.authorEmfietzoglou, D.en
dc.contributor.authorKostarelos, K.en
dc.contributor.authorSgouros, G.en
dc.date.accessioned2015-11-24T19:36:42Z
dc.date.available2015-11-24T19:36:42Z
dc.identifier.issn0161-5505-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/23924
dc.rightsDefault Licence-
dc.subjectAnimalsen
dc.subject*Brachytherapyen
dc.subjectCopper Radioisotopes/diagnostic use/pharmacokineticsen
dc.subjectDrug Carriersen
dc.subjectIodine Radioisotopes/pharmacokinetics/therapeutic useen
dc.subjectLiposomes/*pharmacokineticsen
dc.subjectMiceen
dc.subjectNeoplasms/*radiotherapyen
dc.subjectParticle Sizeen
dc.subjectRadiation Dosageen
dc.subjectRadioisotopes/*pharmacokinetics/therapeutic useen
dc.subjectRhenium/diagnostic use/pharmacokineticsen
dc.subjectTissue Distributionen
dc.subjectYttrium Radioisotopes/diagnostic use/pharmacokineticsen
dc.titleAn analytic dosimetry study for the use of radionuclide-liposome conjugates in internal radiotherapyen
heal.abstractA dosimetric analysis has been performed to evaluate the potential of liposome systems as carriers of radionuclides in internal radiotherapy. METHODS: Pharmacokinetic data for a variety of liposome constructs (multilamellar vesicles [MLV]; small unilamellar vesicles [SUV]; and sterically stabilized liposomes, monosialoganglioside [G(M1)]-coated) were used to obtain tumor and normal-organ absorbed dose estimates for (67)Cu, (188)Re, (90)Y, and (131)I. Dosimetry was performed for two tumor models: subcutaneous Ehrlich ascites tumor, growing intramuscularly, and C26 colon carcinoma, growing intrahepatically. Dose estimates were obtained using the MIRD schema. Tumor doses were obtained assuming local deposition of electron energy; photon contributions were incorporated assuming spheric tumor geometry. With the conservative assumption that intravenously administered liposomes achieve rapid equilibration with the red marrow extracellular fluid volume, red marrow absorbed dose estimates were obtained from blood kinetics. RESULTS: For intramuscular tumors, absorbed dose ratios for tumor to red marrow ranged from 0.93 ((131)I-MLV) to 13.9 ((90)Y-SUV). Tumor-to-liver ratios ranged from 0.08 ((188)Re-MLV) to 0.92 ((188)Re-SUV); corresponding values for tumor to spleen were 0.13 ((90)Y-MLV) and 0.54 ((188)Re-G(M1)). The optimal combination of radionuclide and liposome system was obtained with (90)Y-SUV. Tumor-to-liver ratios for the G(M1)-coated construct were greatest when the tumor was intrahepatic (1.13 for (90)Y). For a given liposome system, absorbed dose ratios for tumor to normal tissue exhibited up to a twofold variation depending on the radionuclide selected. CONCLUSION: This study provides a dosimetric evaluation for the use of some liposome systems as carriers in targeted radionuclide therapy. Although much further work must be undertaken before any clinical application is considered, these results suggest that radionuclide targeting using liposomes is feasible and may have the advantage of reduced red marrow absorbed dose.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/11337529-
heal.journalNameJ Nucl Meden
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2001-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Φόρτωση...
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή: